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Introduction 
  
 The treatment of cancer has been a topic of study for decades due to the devastating 
effects of the disease and the need for a therapeutic regimen that presents maximum efficacy 
with minimal toxicity. For cancer patients, quality of life is disturbed by not only the 
pathogenesis of disease, but also the potential toxic effects on the body as a result of the 
prescribed therapeutic regimen. The quality of life is defined as “the state of well being that is a 
composite of two components; the ability to perform everyday activities that reflect the physical, 
psychological, and social well-being; and patient satisfaction with the levels of functioning and control of 
disease.”(Bottomley, 2010, pg. 102). After a diagnosis of cancer, it is the duty of the nurse to promote 
patient quality of life by minimizing the trauma associated with emotional, physical, and mental strain on 
the body that is induced by cancer progression as well as the chemotherapy regimen.  The notation of 
“presence” is a highlighted nursing skill in which the patient is aware that the nurse is listening, attentive, 
and truly cares for their well-being. Although this nursing skill is a major focus of patient care, 
physiological understanding of the pathogenesis of cancer and manifestations is crucial to providing 
optimal care and patient education. An educational background that includes studies of the pathway of 
disease and the reasoning behind clinical findings will bridge the gap between book knowledge and 
clinical skill. As a part of the interdisciplinary approach, the nurse has the power to combine knowledge 
from pharmacy, research, and medical management into the care plan for their patients, which is why a 
strong educational background covering etiology of the disease is necessary.  
 This project was designed to join together a hands-on laboratory research component 
with advanced training in the clinical skills needed to enhance the quality of life for cancer 
patients.  This report includes descriptions of laboratory observations of Type 1 Topoisomerase 
inhibition and the resulting molecular mechanisms of cytotoxicity on both purified DNA samples 
and cultured hepatic cancer cells, together with a summary of complementary clinical education 
obtained at Memorial Sloan Kettering Cancer Center in New York City during the spring 
semester of 2011. The focus of this report is to enhance patient advocacy by bridging the gap 
between clinical practice and laboratory research aimed at improvements in oncology treatment. 
As an example of an interdisciplinary approach to cancer management, this project combines in-
depth knowledge from laboratory research on novel pharmacological interventions with 
advances in bedside care strategies to model a new opportunity for promoting optimal health and 
quality of life for patients based on improved understanding of the underlying molecular 
mechanisms by clinicians.  
 As research has declared, cancer cells rapidly proliferate in the body. Chemotherapy has been 
proven to preserve life by selectively targeting fast growing cells, which initiates lysis of the cancer cells. 
Unfortunately, cancer cells are not the only rapidly proliferating cells in the body. The term cytotoxicity 
refers to the adverse effects on proliferating healthy cells such as hair follicles, bone marrow, and 
intestinal epithelium, due to the cancer treatment. Among the body systems that are adversely affected by 
chemotherapy, the hematological side effects can be fatal; anemia, thrombocytopenia, and neutropenia 
result from cytotoxic effects on bone marrow. Other common side effects from chemotherapy include 
nausea, fatigue, cachexia, alopecia, and gastro-intestinal issues.  
Type 1 Topoisomerase Inhibitors: 
 The classification of chemotherapy utilized for this research experiment was type 1 
topoisomerase (topo 1) inhibitors, which are largely derived from plant alkaloids. The history of topo 1 
inhibitors stems from research performed in the 1960s. “The early 1960s discovery of camptothecin, 
revealed that this Chinese tree derivative had antitumor activity however, it also caused severe toxic 
effects on the bone marrow and gastrointestinal system. In the late 1980s, topoisomerase I was identified 
as the unambiguous site of action of camptothecin; and this finding renewed interest in the development 
of topo 1 poisons as such drugs may be valuable additions to combination chemotherapy.”(Ulukan & 
Swaan, 2002). Topotecan, a semisynthetic form of the original camptothecin, was FDA approved in 2006 
and has been proven to induce minimal cytotoxic effects on healthy cells of the body. The administration 
of Topotecan has been associated with side effects such as reversible neutropenia (low neutrophil count) 
and thrombocytopenia (low platelet count) as well as mild non-hematological effects including alopecia, 
nausea, and vomiting. 
Mechanism of Action of Topotecan:  
  “Topo 1 enzymes work by binding to specific sites on DNA, forming a break in one strand to 
relieve strain induced by DNA polymerases as the replication fork moves along genomic DNA, thus 
facilitating DNA replication, which is essential for survival of the cell.”[Pommier, 1998]. Topo 1 
inhibitors bind to the topo 1 enzyme to form a “cleavable complex” which stabilizes a single strand break 
in the replicating DNA. As the replication fork progresses, the template strand with the single strand DNA 
break attached to the topo 1 enzyme is unable to religate, causing the progeny DNA strand to have a 
double strand break. “The DNA double strand break, produced by the cleavable complex can be 
converted into irreversible lesion which triggers cell-cycle arrest and death.”(Das, Smitha, Gupta,  et al, 
2009).  
 
 One method to analyze the inhibition of topo 1 enzyme is gel electrophoresis.  This assay allows 
visualization of the effects of topo 1 enzyme inhibition on replicating DNA by the distance traveled along 
the gel. The distance traveled is directly related to the conformation of the DNA, which can be 
supercoiled or relaxed. The relaxation of DNA, promoted by the topo 1 enzyme, and supercoiled DNA, 
promoted by topo 1 inhibitors, can be examined by the mobility of the relaxed double stranded DNA 
through the gel while electric current is applied. The materials needed for gel electrophoresis includes 
20ul samples of DNA per well, 1.2% agarose gel, and the electric power supply of 75-100 Volts. First, the 
1.2% agarose gel is prepared by measuring the appropriate concentration of agarose which is then added 
to TBE 1x buffer. The mixture is then heated until the solution is clear, cooled to 50°C, and poured into 
the tray to harden. The power supply set to 75-100 volts is applied for 45 minutes. 
 
  The electric current runs in the negative-to-positive direction to allow DNA, which is negatively 
charged, to move from one end of the gel (negative) and attract to the other end of the gel (positive); this 
movement allows for clear separation of the bands on the gel. Supercoiled DNA travels faster along the 
gel due to its compact structure as opposed to the relaxed DNA. The topo 1 inhibitors prevent the 
relaxation of replicating DNA induced by topo 1, which promotes supercoiled DNA. As the amount of 
topo 1 inhibitor added to the DNA samples is increased, supercoiled DNA will be apparent on the gel. 
 
 Sample wells: where DNA 
is loaded 
Supercoiled DNA travels faster on the gel 
Relaxed DNA travels slower on the gel 
 The cell cycle consists of 5 phases; resting (G0), preparation for DNA replication through protein 
synthesis (G1), DNA replication (S), enzyme synthesis (G2), and cell division (M). Topo 1 inhibitors 
arrest the cell cycle mainly in S phase, during the process of DNA replication. “Cells can arrest at cell 
cycle checkpoints temporarily to allow for cell damage to be repaired, dissipation of exogenous cellular 
stress signals or to await availability of growth factors. Checkpoint signaling may also result in activation 
of pathways leading to programmed cell death (apoptosis) if cellular damage cannot be properly 
repaired.”(Pietenpol & Stewart, 2002, pg.475). Cell death is induced by the pathways that follow an 
unrepaired double strand break in the DNA. The initial responses to the double strand break in DNA are 
by activation of protein kinases; ATM (ataxia-telangiectasia mutated), DNA Dependant Protein Kinase 
(DNA-PK), and ATR (ataxia-telangiectasia). These protein kinases are then responsible for 
phosphorylating and activating the tumor suppressor protein, p53. A further series of events that are 
stimulated via p53 activation continue to promote cell death. “Several target gene products downstream of 
p53 can promote apoptosis, for example the BAX protein, which is associated with the mitochondrial 
changes mediating cell death.”( Pietenpol & Stewart, 2002, pg.478).  
HepG2 Culture: 
 HepG2 cells, an immortalized cell line derived from liver cancer cells, were cultured and treated 
with specific peptide type topo 1 inhibitors, for assessment of possible toxic effects. “HepG2 was derived 
from the liver tissue of a 15 year-old caucasian male with differentiated hepatocellular carcinoma. These 
cells are epithelial and have model chromosome number of 55.”(Altogen Biosystems, 2008). Liver cells 
are especially useful when studying drug toxicity because many pharmacological treatments are 
metabolized via liver enzymes.  
MATERIALS AND METHODS: 
Tissue Culture-4/25/2011 
• Laminar flow hood 
• CO2 incubator- 37°C/ 5% CO2 
• Nikon Eclipse TS100 Inverted microscope 10x objective power  
• Screwcap flasks (7 total: 3 controls, 4 new) 
• Minimal Essential Medium Eagle (MEM) media+ fetal bovine serum +penicillin (see attached for 
 ingredients) 
• Graduated pipettes (5ml) 
• Vacuum suction 
• Spray bottle of 70% ethanol 
• Gloves 
• Paper towels 
• Cell scraper 
 
 The first step of this procedure was to prepare the hood. The blower and UV light must be turned 
on in order to begin. To prevent contamination, the hood must be kept sterile. First, apply gloves and 
spray paper towels with ethanol until saturated. Then, the hood can be cleaned with the wet paper 
towels, especially cleaning the center of the hood where most of the procedure will take place. I 
obtained three original/control culture flasks labeled Dr Martin (a&b) and student from Dr. Slitt’s lab 
in pharmacy. While maintaining the sterile field, we used the cell scraper to liberate the cells growing 
on the bottom surface of Dr. Martin’s flask. Once the cells were free in suspension, all of the 
remaining media was removed by suction. The remaining cells were bottled in fresh medium by using 
a sterile 5ml pipette and adding 5ml of MEM 1x with additives. Next, the second flask labeled Dr. 
Martin b was transferred using 1ml of suspended cells into a new flask labeled #1. I then scraped the 
cells from the surface of Dr. Martin b flask and transferred 1ml into a second new flask labeled #2. 
The remainder of suspended cells in Dr. Martin b flask was suctioned off, and the attached cells were 
re-fed with 5ml of media. The third original flask labeled student was transferred into new flask 
labeled #3. The remaining cells were scraped off the student flask and 1ml was pipetted into a new 
flask labeled #4. Fresh media was added to each culture, so that each new flask contained 5ml of 
media. Finally, 0.05ml of a 1%  penicillin-streptococcal antibiotic solution was pipette into each 
flask. Lightly screw each flask cap onto the correct flask, just enough so the cap will not fall off, but 
not tight so the cells can breathe. Place into the CO2 incubator and securely close the door. Take as 
little time as possible moving the samples into the incubator because it will beep when the CO2 level 
drops below 5 %. The final result of this procedure was that the original 3 flasks containing cultured 
HepG2 cells were sub-cultured, thinned, and fed with 4 new flasks added to the experiment; 
suspensions of transplanted free cells in flasks #1 &3 and transplanted scraped cells in flasks #2&4.  
Treating the Cells-4/27/2011 
 
• LM2-6 [RLSH-NH2] 
 
 
 
 
• LM2-14 [SLHR-NH2] 
 
  
 The first step was to identify and obtain the two peptides (topo 1 inhibitors) that were used as a 
treatment for the cancer cells. Next, the hood was prepared mimicking the exact technique used for tissue 
culture. Each flask (7 all together) needed to be visualized under the inverted scope prior to treatment 
with topo 1 inhibitors to observe for contamination from the previous week’s tissue culture procedure. 
Observations from the inverted microscope included: 
Flask #2 Clumped up and free 
#1 Free cells possibly 
contaminated 
#3 Growing nicely –possibly 
contaminated 
#4 Clumps growing nicely 
 
 The Dr. Martin (a&b) and student control flasks were quickly observed for potential 
contamination and then replaced in the incubator, with the exception of Dr. Martin A sample which was 
discarded due to bacterial contamination. Both topo1 inhibitors needed to be diluted to make a 1:1000 
mixture. I obtained 2 centrifuge tubes to mix each peptide (1ul) with distilled water (1000ul) to make a 
1:1000 dilution. Each centrifuge tube mixture (one tube/peptide dilution) was vortexed and added to the 
designated flasks #1-4. Flask #1 and 2 were treated first with 500ul/flask of the LM2-6 diluted mixture. 
Next, I obtained the peptide LM2-14 diluted mixture transferred 500ul/flask into flasks 3&4. The treated 
samples were then carefully placed back into the incubator.  
Cell Count-4/25- 5/2/2011 
• Slides- Nexelom CHT4-SD100-004 (2 samples per slide) 
• 20ul pipette 
• Trypan blue 0.4% solution (.040mg/100ml) 
• Nexcelom BioScience (2009) Cellometer  Vision Trio # vision-003-0158with Cellometer® vision 
software DOC # 8001198 REV: 090409 
• Nikon Eclipse TE2000-E 10x Inverted Microscope with Camera 
 On 4/25/2011, a 1ml sample of the supernatant from the Dr. Martin B untreated control flask was 
taken to be counted on the Nexcelom cellometer. The setup for cell counting needed to be prepared prior 
to counting the samples. The power button located in the back of the cellometer machine must be turned 
on which is indicated by a light source where the slide enters the machine. The computer setup must 
match the correct assay that will be performed in order to count the cell samples. The setup on the 
computer software included: 
Assay Type Assay #01_Concentration 
Description Total Cell Concentration without trypan blue 
Cell Type Cell line _assay #01 
 
 After the computer setup was complete, 
the sample was added to the slide using a 20ul pipette. Each slide holds 
exactly 20ul. The 20ul sample is applied to the circle indicated on the 
slide.  
 
 
 The loaded slide was then inserted into the machine. 
Next, I selected the PREVIEW BRIGHTFIELD option located under the setup options 
of the assay. The image of the cells on the slide appeared on the computer screen, 
which then needed to be focused manually by the black dial on the right side of the 
cellometer.  
 
 In order to focus properly, the cells needed to have a white 
interior with a dark border. It was also important to decipher cells from 
debris in order to focus correctly. Once the focus was determined, the 
COUNT option underneath the image was selected. The meter takes the 
cell count based on the focus applied. Time needed for cell counting was  
    about 2 minutes per sample.  
 
 The results from the cell count performed on 4/25/2011 of supernatant from Dr. Martin B 
untreated control flask included: 
Cell Count 114cells 
Mean Cell Size 9.3 microns 
Concentration 1.61E+05 cells/ml 
  The parameter of cell size based on this test provided the information needed to focus the cell 
count for the treated samples tested on 4/29/2011. The new assay stored in the computer included: 
Assay Type HepG2 JG Cells 
Description hepatocytes 
Cell Type HepG2 JG Cells with trypan blue viability 
Cell Diameter 3-10microns 
 
 On 5/2/2011, 1ml of sample from each tissue culture (6 remaining) was put into centrifuge tubes, 
labeling each appropriately while maintaining a sterile environment in the hood. The cellometer had 
already been set to the appropriate assay that was saved on 4/25/2011. All of the samples were then mixed 
with trypan blue in order to detect dead cells from living cells. “Trypan blue is a vital dye. The reactivity 
of trypan blue is based on the fact that the chromopore is negatively charged and does not interact with 
the cell unless the membrane is damaged. Therefore, all the cells which exclude the dye are 
viable.”(Freshney, 1987).  On each sample slide, 18ul of sample was applied with 2ul of trypan blue. The 
slide was placed into the cellometer and the appropriate steps were initiated; PREVIEW BIRGHTFIELD, 
focus, and COUNT.  The results recorded from the counts performed on 5/2/2011 are as follows: 
 
 
 
 
Student 
Live cell count 280 cells 
Dead cell count 30 cells 
Mean live cell size 6.9 microns 
Mean dead cell size 5.4 microns 
Viability 90.3% 
Concentration 3.92E+05 cells/ml 
Sample 2-Scraped Cells  
Treated with LM2-6 
Live cell count 267 cells 
Dead cell count 394 cells 
Mean live cell size 5.5 microns 
Mean dead cell size 5.9 microns 
Viability 40.4% 
Concentration 3.72E+05 cells/ml Sample 1-Free Cells Treated with LM2-6 
Live cell count 4948 cells 
Dead cell count 2841 cells 
Mean live cell size 5.4 microns 
Mean dead cell size 5.7 microns 
Viability 63.5% 
  
 
 
 
The cell counts were photographed using the Nexelom Cellometer. Green indicated live cells; 
yellow was the raw image of debris/cells that the cellometer recognized but didn’t include in the count; 
and red was dead cells. 
Concentration 6.90E+06 cells/ml 
Sample 3-Free Cells Treated with LM2-14 
Live cell count 451 cells 
Dead cell count 223 cells 
Mean live cell size 5.7 microns 
Mean dead cell size 6.1 microns 
Viability 66.9% 
Concentration 6.29E+05 cells/ml 
Sample 4-Scraped Cells  
Treated with LM2-14 
Live cell count 2607 cells 
Dead cell count 1082 cells 
Mean live cell size 6.2 microns 
Mean dead cell size 5.4 microns 
Viability 70.7% 
Concentration 3.64E+06 cells/ml 
Sample 3 Scraped Cells treated with LM2-14 
Sample 1-Scraped Cells treated with LM2-6 
Sample 4-Scraped Cells treates with LM2-14 
Photographs by Nikon Eclipse TE2000-E 10x Inverted 
Microscope  
 
 
 
Photographs by Nexcelom BioScience Cellometer Vision 
 Results and Conclusion: 
 The purpose of this project was to combine clinical knowledge regarding the nursing 
management for chemotherapy induced side effects with laboratory research utilizing HepG2 cell cultures 
treated with topo 1 inhibitors. By joining clinical and research experience, an optimal patient care model 
was made, which focuses on the quality of life for cancer patients by examining the toxicity of topo 1 
inhibitors on the HepG2 cell cultures and linking the results to potential clinical manifestations based on 
the mechanism of action of the drug.   
 After analyzing the results from the cell count obtained on 5/2/2011, Sample 1 (free cells treated 
with LM2-6) displayed a convincing cell count with a concentration of 6.90E+06cell/ml. The ratio of live: 
dead cell count was also in the expected range (4948:2841). Sample 4 (scraped cells treated with LM2-
14) also revealed a believable cell count with a concentration of 3.64E+06 cells/ml and live: dead ratio of 
2607:1082. Although the numbers obtained from the Nexcelom Cellometer for samples 1 and 4 seemed 
appropriate, the images taken by the cell counter displayed the potential room for error. The images 
allowed for anaylization of the actual cells that were counted by the machine, based on the manual focus. 
As the eye can see, not all of the actual cells on the slide were counted. Debris, identified by its irregular 
shape as compared to the other cells counted, was also included in the cell count. As stated previously, the 
cell count is directly correlated to the manual focus of the slide. For samples 2,3, and the student control, 
the cell counts were unreliable due to the possibility of a poor focus. Also, the image displayed for sample 
4 shows that the cells not in the clumped region were not counted. As opposed to the Nexcelom 
Cellometer cell count, the inverted microscope portrayed the striking cell death of sample 1(free cell 
treated with LM2-6). Under the microscope, cells were unable to be identified by two different people. 
This result indicates that the peptide LM2-6 topo 1 inhibitor was extremely toxic to the HepG2 free cells, 
providing a viable option for further investigation as a chemotherapy agent. Although the scraped cells 
treated with LM2-6 were not completely killed, the structure of the nucleus changed, as evidenced by 
multiple nuclei in one membrane. “Apoptosis is characterized by typical morphological and biochemical 
changes including cell shrinkage, nuclear DNA fragmentation, and membrane 
blebbing.”(Debatin&Krammer, 2004). The cells treated with LM2-14 did not provide as stimulating 
results as LM2-6 with the inverted microscope. The scraped cells treated with LM2-14 were clumped and 
did not seem to be effected by the treatment. The free cells treated with LM2-14 were growing normally 
with little-to-no indication of treatment effects. Although the cell counts were not deemed as reliable 
results due to count and focus error, the micron size of the cells treated with LM2-14 did not vary much 
from the micron size of the student control cells. This also provides a sense that the cells were not highly 
affected by the LM2-14 peptide. The micron size of free and scraped cells treated with LM2-6 
demonstrated a substantial decrease in micron size as compared to the student control.  
 Implications for further research include testing the LM2-6 peptide for toxicity on normal cells. 
The results displayed the toxic effects on the free and scraped cells that were treated by this peptide. 
Although the peptide demonstrated maximum efficacy while killing the free HepG2 cells at 6 days post 
treatment, it needs further testing to monitor the effect that this potential chemotherapy agent will have on 
normal tissue. The cells treated with this peptide in the future should also be tested for mitochondrial 
activity, which provides an accurate precursor to cell death.  
 Patient advocacy is not limited to bedside care. This project provides a model for health care 
professionals to encompass when implementing care for cancer patients. The chemotherapy agents 
administered in the hospital setting have various side effects on patients, which are determined by the 
mechanism of action of the drug. It is essential for health care professionals to move into a focused plan 
of care for patients based on the understanding of the molecular pathway of the administered 
chemotherapy. In this way, the many disciplines of science can merge to form a higher level of patient 
advocacy, through clinical practice and laboratory research, in order to enhance the quality of life for 
cancer patients. 
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